• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, Sept. 3 Bharat Biotech International Ltd (BBIL) has launched two new vaccines, BioHib, the first indigenously developed and manufactured Haemophilus Influenza type b (Hib) vaccine in the country, and a tetravalent combination vaccine, Comvac4-HB.

The entire development of BioHib was handled in-house by the Hyderabad-based company which had invested “several millions of dollars over last four years,” according to a release.

Haemophilus influenza type b (Hib) bacterium causes serious disease, often life-threatening illnesses in young children including meningitis and severe pneumonia.

“BioHib has the ability to save the lives of millions of children worldwide at a very affordable price. The tetravalent and pentavalent vaccines give us the ability to protect children against multiple infectious diseases with a single injection,” Mr Krishna M. Ella, Chairman and Managing Director, Bharat Biotech, said.

More Stories on : Announcements | New Products & Services | Pharmaceuticals | Health

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Bharat Biotech launches 2 vaccines

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line